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Summary
A 30 year old asymptomatic male with stage 3 chronic kidney disease (CKD) secondary to Focal Segmental Glomerulosclerosis
was found to have features of CKD associated cardiomyopathy including left ventricular hypertrophy (LVH) and focal sub-
endocardial scarring on cardiacmagnetic resonance imaging. There was also a significantly raised CT coronary calcium score and
evidence of non-flow limiting coronary artery disease (CAD) on a CT coronary angiogram. Early stage CKD is amajor risk factor
for cardiovascular risk causingmyocardial hypertrophy and fibrosis and coronary artery atheroma. Cardiovascular risk begins to
increase from an eGFR of around 75ml/min/1.73m2. The pathophysiology of cardiovascular disease in CKD is under investigation
but to date, treatment options are limited. Blood pressure control and statins have the strongest supportive evidence.
Introduction
The leading cause of death in patients with end-stage renal dis-
ease (ESRD) is cardiovascular disease.1 Sudden cardiac death,
arrhythmia and congestive cardiac failure are more common
than myocardial infarction (MI) suggesting that it is left ven-
tricular disease (CKD-associated cardiomyopathy) rather than
CAD that has the greater clinical impact.2 Cardiac imaging tech-
niques have demonstrated that a large majority of patients with
ESRD have structural and functional myocardial abnormalities
and often evidence of accelerated CAD.3 Only more recently has
it been appreciated that cardiovascular risk is also elevated in
patients with early stage CKD and that early features of myocar-
dial and coronary disease are common. Severe cardiovascular
disease may be present even in young asymptomatic patients
with early stage CKD.
Case vignette
A 30-year-old non-smoking male was referred to hospital renal
services due to a reduced estimated glomerular filtration rate
(eGFR) of 57ml/min/1.73 m2 and heavy proteinuria (albumin
creatinine ratio 120.3mg/mmol, albumin 40g/l). There was no
significant past medical history. He was hypertensive (164/72)
but not obese. His total cholesterol was 5.3mmol/l and triglycer-
ides 1.10mmol/l. He was started on losartan with initial ad-
equate blood pressure (BP) control (129/84) but continued to
have proteinuria. A renal biopsy showed focal segmental glo-
merulosclerosis (FSGS). A cardiac magnetic resonance (CMR)
scan demonstrated concentric LVH with a maximal segmental
wall thickness of 16mm in the basal septum and an elevated
left ventricular mass of 108 g/m2 (normal range for age and gen-
der 40–97 g/m2). Systolic function was good with an ejection
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fraction of 61% and 3D global longitudinal strain (GLS) of
15.06%. There was however, hypokinesia of the mid-inferior
and inferolateral segments without associated thinning.
Following administration of intravenous gadolinium contrast
there was focal sub-endocardial late enhancement in the basal
and mid-inferior segment corresponding with the segments of
hypokinesia (see Figure 1). These findings raised the possibility
of MI due to CAD. A CT coronary angiogram (CTCA) showed
moderate coronary calcification with an Agatston score of 112.
There was evidence of mild diffuse coronary atheroma but no
flow limiting stenosis within the main coronary arteries.
Discussion
The high prevalence of cardiovascular disease in ESRD was iden-
tified in the 1970s early after the introduction of dialysis and was
found to be the result of left ventricular disease (CKD-associated
cardiomyopathy) and accelerated atherosclerosis.2,4 It is now the
most common cause of death in this group with a prevalence of
between 10 and 100 times control groups according to age.5,6
Only in recent years has the elevated cardiovascular risk of pa-
tients with early stage CKD been identified. There is a graded re-
lationship between the degree of cardiovascular risk and eGFR so
that the risk of early stage CKD is much lower than that of ESRD.7
In early stage CKD, left ventricular mass is frequently ele-
vated and the reported prevalence of LVH by echocardiography
is 32%.2 Studies using echocardiography and CMR in subjects
with CKD stages 2 and 3 have shown that although LV ejection
fraction is preserved compared to controls, other indices of sys-
tolic function including GLS (a marker of regional contractility)
are abnormal.8 In an echocardiographic study of patients with
stage 2 and 3 CKD Edwards et al. 9 showed that both arterial and
left ventricular end systolic elastances (stiffness) were
increased with a preserved coupling ratio but at the expense of
LV stiffness and haemodynamic instability, a pattern resem-
bling heart failure with preserved ejection fraction. Diastolic fill-
ing velocities were reduced compared to controls while E/e0 was
increased.9 E/e0 is the ratio of mitral early filling maximal vel-
ocity to early myocardial relaxation velocity of the lateral mitral
annulus and is an index of left atrial pressure. More recently,
the application of T1 mapping CMR has allowed better
characterization of the myocardium than with standard late
gadolinium enhancement inversion recovery imaging. In a
small cross-sectional study, Edwards et al.8 demonstrated an in-
crease in extracellular volume (biomarker of diffuse interstitial
fibrosis) with CKD compared to age and gender matched
healthy controls and hypertensive subjects with normal renal
function. This was correlated with a reduction in GLS.8
Furthermore, while gadolinium contrast agents are contraindi-
cated in patients with ESRD due to previous reports of nephro-
genic systemic fibrosis, native T1 mapping (without contrast)
evades this issue.10 In a study of 28 haemodialysis patients
compared to 33 age and gender-matched controls Rutherford
et al.10 found significantly higher global and septal T1 values
indicating diffuse fibrosis.
While novel techniques allow further insights into the struc-
tural changes seen with CKD-associated cardiomyopathy the
pathophysiology of CKD-associated cardiomyopathy remains
complex and multifactorial. To date, there is evidence supporting
a disordered renin–angiotensin aldosterone system, altered cal-
cium and phosphate metabolism (causing high levels of fibroblast
growth factor 23 and parathyroid hormone) and hypertension.11
Effective treatment is still lacking. While angiotensin-converting
enzyme (ACE) inhibition causes regression of left ventricular
mass in those without CKD no such effect has been shown in
CKD.12 ACE inhibition, however, still has a pivotal role in theman-
agement of CKD due to its antihypertensive and antiproteinuric
effects which slow the progression of CKD.13 The addition of spir-
onolactone to an ACE inhibitor or angiotensin receptor blocker
(ARB) is promising. In a randomized blinded, placebo-controlled
trial of patients with CKD stage 2 and 3, it reduced arterial
stiffness and left ventricular mass with only rare associated
hyperkalaemia.14
Early stage CKD is probably also an independent risk factor
for CAD.15 In the ARIC study, the hazard ratios for atheroscler-
otic events were 1.38 and 1.16 for subjects with CKD stages 3–4
and 2, respectively.16 An analysis of Framingham data however,
found early stage CKD to be strongly associated with coronary
risk factors but it was not independently associated with cardio-
vascular events.17 In patients with established CAD, those with
CKD tend to have more severe disease.18 CKD was associated
with was an increase in mortality and re-infarction in almost
40, 000 patients recorded in databases of four acute coronary
syndrome trials.19 There was an independent association of cre-
atinine clearance with the hazard ratio for death at 180days for
both ST-elevation MI and non-ST elevation MI.19 The increased
calcium score on CTCA in this patient is in keeping with previ-
ous studies which demonstrated calcium scores could be 8
times higher than those without CKD.20 The high prevalence
and early onset of CAD in CKD is likely to be a combination of
systemic inflammation, oxidative stress, hypertension, vascular
calcification and disorders in bone metabolism.21
Management of CAD in CKD is challenging due to a lack of
evidence.22 Despite the large studies supporting the use of as-
pirin, statins, ACE inhibition and beta blockade for those with-
out CKD, patients with CKD are less likely to be started on such
medications despite higher risks.22 Patients with CKD are often
excluded from major cardiovascular studies.22 A recent meta-
analysis of 50 studies found that antiplatelet agents reduced the
risk of MI by 13% (a lower figure than the general population)
but the risk of major bleeding was increased regardless of the of
antiplatelet agent used or the stage of CKD.23 In addition Kim
et al.24 found aspirin could have an adverse effect on renal func-
tion. Evidence for statins is a little clearer. Although randomized
studies in dialysis patients found no reduction in death, non-
fatal MI or stroke following the reduction of LDL the large Study
of Heart and Renal Protection (SHARP), showed that the combin-
ation of simvastatin and ezetimibe caused a highly significant
17% reduction in atherosclerotic events.25,26 In SHARP the ef-
fects of statins on events was similar in both dialysis and non-
dialysis patients but a meta-analysis showed that the reduction
Figure 1. Focal sub-endocardial late gadolinium enhancement in the mid-infer-
ior segment within the right coronary artery territory.
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in major vascular events fell as the eGFR decreased, suggesting
that subjects with early stage CKD gain most benefit.25 More re-
cently a meta-analysis conducted by the Cholesterol Treatment
Trialists Collaboration including 183 419 patients from 28 trials
concluded that overall statin therapy reduced the first vascular
event by over 20% in patients with CKD.27 The effect reduced as
eGFR declined meaning there was little advantage for patients
on dialysis.27
This young patient already has evidence of both CKD-
associated cardiomyopathy with LVH and scarring and premature
CAD with a possible previous MI. He is asymptomatic and none of
these abnormalities were evident on routine clinical examination
or ECG. There are no current guidelines on screening patients with
early stage CKD for cardiac disease but this case should serve to
remind all nephrologists of the need to be vigilant; subjects with
early stage CKD are usually far more likely to die of premature
cardiovascular disease (13-fold) than to progress to ESRD.1
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